 CAMBRIDGE, Mass., Nov. 11, 2020 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation to SRF388 for the treatment of patients with hepatocellular carcinoma HCC, or liver cancer, who have been previously treated with standard therapies, such as vascular endothelial growth factor targeted agents and programmed death-ligand PD-L1 blockade. 